JP2023526536A - 呼吸器免疫病態の吸入型ｉｌ－１遮断治療 - Google Patents

呼吸器免疫病態の吸入型ｉｌ－１遮断治療 Download PDF

Info

Publication number
JP2023526536A
JP2023526536A JP2022571335A JP2022571335A JP2023526536A JP 2023526536 A JP2023526536 A JP 2023526536A JP 2022571335 A JP2022571335 A JP 2022571335A JP 2022571335 A JP2022571335 A JP 2022571335A JP 2023526536 A JP2023526536 A JP 2023526536A
Authority
JP
Japan
Prior art keywords
nebulizer
rhil
anakinra
nebulized
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022571335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526536A5 (enExample
Inventor
リング、スティーヴン、エー．
バラノウスキ、リン、エー．
クライザー、ケイトリン、アール．
パラシオス、ミッシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altavant Sciences GmbH
Original Assignee
Altavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences GmbH filed Critical Altavant Sciences GmbH
Publication of JP2023526536A publication Critical patent/JP2023526536A/ja
Publication of JP2023526536A5 publication Critical patent/JP2023526536A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022571335A 2020-05-21 2021-05-20 呼吸器免疫病態の吸入型ｉｌ－１遮断治療 Withdrawn JP2023526536A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063028494P 2020-05-21 2020-05-21
US63/028,494 2020-05-21
US202063072895P 2020-08-31 2020-08-31
US63/072,895 2020-08-31
PCT/IB2021/000347 WO2021234457A1 (en) 2020-05-21 2021-05-20 An inhaled il-1 blockade treatment for respiratory tract immunopathology

Publications (2)

Publication Number Publication Date
JP2023526536A true JP2023526536A (ja) 2023-06-21
JP2023526536A5 JP2023526536A5 (enExample) 2024-05-28

Family

ID=76807913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571335A Withdrawn JP2023526536A (ja) 2020-05-21 2021-05-20 呼吸器免疫病態の吸入型ｉｌ－１遮断治療

Country Status (9)

Country Link
US (1) US20230210768A1 (enExample)
EP (1) EP4153213A1 (enExample)
JP (1) JP2023526536A (enExample)
KR (1) KR20230015397A (enExample)
CN (1) CN116348144A (enExample)
AU (1) AU2021277585A1 (enExample)
CA (1) CA3178404A1 (enExample)
MX (1) MX2022014626A (enExample)
WO (1) WO2021234457A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
HUE048024T2 (hu) * 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Also Published As

Publication number Publication date
AU2021277585A1 (en) 2022-12-15
WO2021234457A1 (en) 2021-11-25
US20230210768A1 (en) 2023-07-06
MX2022014626A (es) 2023-02-22
KR20230015397A (ko) 2023-01-31
CN116348144A (zh) 2023-06-27
CA3178404A1 (en) 2021-11-25
EP4153213A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
CN100333790C (zh) 含白细胞介素－2的药物组合物在制药中的应用
JP6186458B2 (ja) 吸入用の一価金属カチオン乾燥粉末
JP2011057695A (ja) 呼吸器の症状を治療又は予防する方法
CA2555841A1 (en) Interleukin-13 antagonist powders, spray-dried particles, and methods
Ferrati et al. Dosing considerations for inhaled biologics
US20220409627A1 (en) Treatment of lower airways disorders
JP2023526536A (ja) 呼吸器免疫病態の吸入型ｉｌ－１遮断治療
Siekmeier et al. Treatment of systemic diseases by inhalation of biomolecule aerosols
US12005049B2 (en) Methods of preventing cancer metastasis
KR20230011929A (ko) 간질성 폐 질환의 치료에 사용하기 위한 트레프로스티닐
US11365248B2 (en) Formulation of tocilizumab and method for treating COVID-19 by inhalation
US20220339099A1 (en) Compositions of interleukin-1 receptor antagonist
HK40095595A (zh) 用於呼吸道免疫病理学的吸入性il-1阻滞治疗
CN115916243A (zh) 含有速效胰岛素类似物的组合物
TW202241490A (zh) 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物
KR20230118167A (ko) 다목적 적용을 위한 제형
US20210322309A1 (en) Inhalable Formulation of a Solution Containing Olodaterol

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241010